COMPOSITION
Ceftisin Injectable Suspension is a white - cream colored, ready to use sterile suspension after shaking. Each ml contains ceftiofur HCl equivalent to 50 mg of ceftiofur.
INDICATIONS FOR USE
Ceftisin Injectable Suspension is used in cattle for conditions sensitive to ceftiofur;
- For the treatment of bacterial respiratory disease associated with Mannheimia haemolytica (previously Pasteurella haemolytica), Pasteurella multocida and Histophilus somni (previously Haemophilus somnus)
- For the treatment of acute interdigital necrobacillosis (panaritium, foot rot), associated with Fusobacterium necrophorum and Bacteroides melaninogenicus (Porphyromonas asaccharolytica).
- For treatment of acute post-partum (puerperal) metritis within 10 days after calving associated with Escherichia coli, Arcanobacterium pyogenes and Fusobacterium necrophorum and where treatment with other antibiotics has failed.
ADMINISTRATION ROUTES AND AMOUNTS
Before use, shake the bottle vigorously for no more than 60 seconds or until adequately suspended.
For accurate dosing, body weights of animals should be measured as accurately as possible.
Respiratory system infections: Subcutaneously for 3-5 days at a dose of 1 mg/kg body weight per day (1 ml of product per day for every 50 kg body weight).
Acute interdigital necrobacillosis: Subcutaneously for 3 days at a dose of 1 mg/kg body weight per day (1 ml of product per day per 50 kg body weight).
Acute post-partum metritis (within 10 days after calving): subcutaneously for 5 days at a dose of 1 mg/kg body weight per day (1 ml of product per day for every 50 kg of body weight). In some cases, supportive therapy may be required for this infection.
No more than 10 ml should be injected into one injection site. Injections on different days should be done in different areas.
SPECIAL CLINICAL INFORMATION AND SPECIFIC WARNINGS FOR TARGET SPECIES
Before use, shake the bottle well to return it to suspension.
In case of the occurrence of allergic reaction the treatment should be withdrawn.
The product selects for resistant strains such as bacteria carrying extended spectrum beta-lactamases and may constitute a risk to human health if these strains disseminate to humans e.g. via food. For this reason, the product should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly (very acute cases when treatment must be initiated without bacteriological diagnosis) to first line treatment.
Regional and national antimicrobial policies should be taken into account when the product is used. Increased use, including use of the product deviating from the instructions, may increase the prevalence of such resistance. Whenever possible, the product should be used based on susceptibility testing.It is not used for prophylaxis in case of retained placenta.
The product is intended for treatment of individual animals. Do not use for disease prevention or as a part of herd health programmes. Treatment of groups of animals should be strictly restricted to ongoing disease outbreaks according to the approved conditions of use.
WITHDRAWAL PERIOD(S)
Cattle should not be sent to slaughter during the treatment and 8 days after the last drug application. Withdrawal period is “0” days for milk.
MARKETING PACKAGING
Sold as 50 ml, 100 ml and 250 ml type II amber glass vials closed with a bromobutyl rubber stopper and a aluminum flip-off cap in a cardboard box.
